Clinical Study of Nanocrystalline Megestrol in Malnourished Patients With First-Line Non-Small Cell Lung Cancer

Clinical Study of Nanocrystalline Megestrol in Malnourished Patients With First-Line Non-Small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT06828757 by Hunan Province Tumor Hospital, with a registry enrolment figure of 94 participants, started 2025-05-01 and due to reach its primary completion in 2026-12-31. Interventions recorded: nanocrystalline megestrol oral suspension + PD-1/L1 inhibitor combined with chemotherapy; PD-1/L1 inhibitor combined with chemotherapy. Conditions listed: Non Small Cell Lung Cancer. Primary outcome: Appetite improvement level; Weight improvement level. Lung eligibility wording from the registry: "(5) According to the 8th edition of the TNM stage classification of lung cancer with histological or cytologic evidence that cannot undergo complete surgical resection and cannot undergo radical synchronous/sequential chemoradiation and treatment ( IIIB/IIIC phase), metastatic (IV phase) NSCLC". Sites: China. No results are recorded here; the registry entry is the source.